Omeprazole Genoptim (Omeprazole Sodium)

Omeprazole irreversibly inhibits the gastric H+/K+ ATPase (proton pump) in parietal cells, which is the final step in acid secretion. By blocking this enzyme, it markedly reduces both basal and stimulated gastric acid output, raising gastric pH and allowing ulcer healing and symptom relief.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, severity, and response. Dosing is individualized and should follow local clinical guidelines and the prescriber’s judgment.

Safety data for intravenous omeprazole in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Omeprazole is a proton pump inhibitor, offering more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other IV PPIs, its efficacy and safety profile are similar, but formulation differences may affect stability and infusion requirements.

Store the intravenous solution at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from light, moisture, and extreme temperatures. Do not freeze; use within the expiry date after opening as indicated on the label.

The medication is given by intravenous infusion. The solution is diluted according to the manufacturer’s instructions and administered over a period typically ranging from 30 minutes to several hours, depending on the clinical setting and prescribed dose.

Serious adverse events include Clostridioides difficile‑associated colitis, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, hepatic injury, neutropenia, thrombocytopenia, and acute interstitial nephritis. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to omeprazole, other proton pump inhibitors, or any component of the formulation should avoid use. Caution is also advised for individuals with severe hepatic impairment, as well as those taking medications that may have critical interactions, such as clopidogrel or atazanavir, without appropriate monitoring.